Investing in biotech stocks isn't for everyone. An unsuccessful clinical trial can cause a huge decline. The competition is ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Vertex Pharmaceuticals Inc. closed $45.72 below its 52-week high ($510.64), which the company achieved on August 1st.

Robert W. Baird has recently initiated Vertex Inc (VERX) stock to Outperform rating, as announced on July 23, 2024, according to Finviz. Earlier, on March 1, 2024, BofA Securities had raised the stock ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $508.38, a high estimate of ...

CRISPR stock skyrocketed to $199 in 2021, but has since fallen 74% to its current price of $50. This gives the firm a $4.3bn ...

In a report released today, Brian Abrahams from RBC Capital maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), ...

This was the stock's second consecutive day of losses.

According to Benzinga Pro, Vertex Pharmaceuticals's peer group average for short interest as a percentage of float is 6.15%, ...

CRISPR Therapeutics' stock may seem boring due to slow FDA trial and rollout process, but it's a strong long-term investment.

As global markets rebound from recent sell-offs, technology stocks have led the charge, significantly outpacing their value counterparts. With the S&P 500 Index recovering from its steepest decline ...

TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” second ...